查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969252

基因編輯市場：按 CRISPR 技術、應用和最終用戶分類 - 2026-2032 年全球預測

Gene Editing Market by CRISPR, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因編輯市場價值將達到 108.9 億美元，到 2026 年將成長到 129.2 億美元，到 2032 年將達到 368.5 億美元，複合年成長率為 19.02%。

主要市場統計數據
基準年 2025 108.9億美元
預計年份：2026年 129.2億美元
預測年份 2032 368.5億美元
複合年成長率 (%) 19.02%

基因編輯領域清晰權威的指南，全面涵蓋技術進步、不斷變化的管治以及不同相關人員的實際優先事項。

基因編輯技術已從小眾科學探索發展成為重塑生物醫學研究、農業生物技術和工業生物科學的核心能力。基於可程式設計核酸酶和RNA引導系統，這項基礎科學如今能夠對多種基因組和細胞類型進行精確修飾，加速假設檢驗並推動新治療方法的開發。作為對此趨勢的介紹，本報告重點關注其底層技術、轉換流程、法律規範以及不斷發展的供應商、服務供應商和終端用戶生態系統之間的互動。

對正在積極重新定義發展重點和轉化風險概況的關鍵技術、營運和監管轉折點進行深入綜合分析。

基因編輯技術的技術和製度演進的最後階段正在帶來若干變革性轉變，從根本上改變了研發和商業化各個階段的策略考量。首先，編輯技術的改進（包括可減少基因組環境附帶損傷的精準編輯技術的進步）已將重點從概念驗證轉移到最佳化安全性和有效性範圍。開發人員現在將正交檢驗方法、高解析度脫靶評估和全面的功能表徵作為轉化決策的先決條件。

對關稅調整對基因編輯開發整個生命週期中的供應鏈韌性、籌資策略和營運連續性的影響進行嚴格分析。

調整進口關稅和貿易壁壘的政策變化會對整個研發生態系統產生複雜的影響。當美國實施關稅調整時，最直接的影響體現在實驗室運作所需的專用設備、試劑和耗材的採購和分銷方面。依賴進口設備和原料的實驗室將面臨採購成本增加和潛在的延誤，導致前置作業時間延長、庫存緩衝增加以及供應商選擇流程更加複雜。

透過多維細分框架對開發資源進行策略性分配，明確技術選擇、應用需求和最終使用者行為。

細分市場為理解基因編輯技術的技術路徑和應用主導的優先事項提供了一個切實可行的觀點。基於 CRISPR 的市場分析通常著重於 Cas12、Cas13 和 Cas9，它們各自展現出獨特的生化特性、標靶特異性和應用適用性。儘管 Cas9 在許多情況下仍然是 DNA 編輯的通用核酸酶，但 Cas12 和 Cas13 擴展了單鏈標靶化和 RNA 編輯能力，從而能夠實現減少永久性基因組修飾和支持瞬時調控策略的方法。

區域比較評估突顯了不同地區在法規、基礎設施優勢以及全球樞紐商業性和實際擴張的策略路徑方面的細微差異。

區域趨勢透過監管立場、人才庫、資金籌措生態系統和產業基礎設施的差異，影響基因編輯領域的創新軌跡和營運選擇。在美洲，監管路徑與強勁的私人投資和密集的臨床開發生態系統緊密相連，二者共同加速轉化項目，並為基礎技術和服務創造穩健的市場。機構審查框架和集中式監管機構為臨床應用提供了可預測的路徑，而豐富的創業投資環境則支持平台公司和高風險、高回報計劃的快速擴張。

對企業行為和夥伴關係模式進行策略探索，揭示平台開發者、服務供應商和臨床贊助商如何合作推動轉換進度。

基因編輯生態系中的企業行為因其策略方向、資本結構和營運能力而異。工具和試劑供應商專注於平台可靠性、批間一致性以及法規合規性文件，以滿足探索性研究實驗室和受監管生產的需求。這些供應商投資於品質系統和技術支援，以降低准入門檻，並幫助客戶滿足日益嚴格的檢驗要求。服務供應商和契約製造則優先考慮產能、製程穩健性和合規準備，以支援客戶從臨床前生產過渡到受監管的臨床生產。

一系列可操作、有影響力的建議，營運經理和專案團隊可以立即實施：加強轉化研究的準備工作並降低風險。

研究機構和產業界的領導者必須採取實際行動，將科學潛力轉化為永續的成果。首先，投資於整合分子表徵、正交功能分析和標準化脫靶分析的檢驗框架。這有助於降低後續風險，並加強監管合規的基礎。其次，儘早實現關鍵試劑和設備的供應商多元化，並驗證替代來源的合格，以減輕採購衝擊，維持研究的連續性。第三，將發行策略與分子設計同步進行。遞送技術和基因編輯化學的協同開發通常比順序開發更能帶來可預測的轉換進展。

透過整合文獻摘要、專家訪談和跨細分分析，我們透過透明、以證據為導向的調查方法，創造出可操作的見解。

支持這些發現的研究途徑結合了系統性的二手文獻研究、有針對性的專家對話和迭代整合，以確保可靠的證據基礎。二手文獻分析利用了同行評審的文獻、監管指導文件、專利申請和技術白皮書，以繪製技術發展軌跡並識別檢驗方法和發行策略中的反覆出現的主題。這項基礎性綜述建立了一個通用的知識庫，並突顯了需要更深入的質性研究的領域。

這是一份簡潔、綜合的分析報告，它透過連接技術進步、營運準備和監管合作，提出了負責任地推進基因編輯計畫的連貫藍圖。

基因編輯技術正處於策略轉折點，技術能力、監管進步和營運規範在此交匯，決定哪些項目能夠從實驗室概念驗證走向實際應用。該領域的成熟不僅需要持續的技術創新，還需要嚴謹的營運實踐、與監管機構的積極合作以及彌合能力差距的策略夥伴關係。那些能夠協調分子設計和發行策略、實現供應鏈多元化並優先考慮嚴格檢驗的機構，可以降低轉化風險，提高專案成功的可能性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因編輯市場：CRISPR

  • Cas12
  • Cas13
  • Cas9

第9章 基因編輯市場：依技術分類

  • 反義寡核苷酸
  • CRISPR-Cas9
  • Meganucleases
  • RNA引導的核酸酶
  • TALENs（轉錄活化因子樣效應核酸酶）
  • ZFN（鋅指核酸酶）

第10章 基因編輯市場：依應用領域分類

  • 動物基因工程
  • 基礎研究
  • 生質能源
  • 細胞株工程
  • 診斷
  • 藥物研發
  • 基因編輯
  • 植物性因工程
  • 疫苗研發

第11章 基因編輯市場：依最終使用者分類

  • 學術和政府附屬研究機構
  • 生物技術和製藥公司
  • 受託研究機構（CRO）

第12章 基因編輯市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因編輯市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因編輯市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因編輯市場

第16章：中國基因編輯市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • Illumina, Inc.
  • Lonza Group AG
  • Merck KGaA
  • New England Biolabs, Inc.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-535C6291877E

The Gene Editing Market was valued at USD 10.89 billion in 2025 and is projected to grow to USD 12.92 billion in 2026, with a CAGR of 19.02%, reaching USD 36.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.89 billion
Estimated Year [2026] USD 12.92 billion
Forecast Year [2032] USD 36.85 billion
CAGR (%) 19.02%

A clear and authoritative orientation to the gene editing landscape that frames technological progress, governance shifts, and practical priorities for varied stakeholders

Gene editing has transitioned from a niche scientific pursuit to a central capability that reshapes biomedical research, agricultural biotechnology, and industrial biosciences. The underlying science, anchored by programmable nucleases and RNA-guided systems, now enables precise modifications across a range of genomes and cell types, accelerating hypothesis testing and enabling novel therapeutic modalities. As an introduction to this landscape, the focus here is on the interplay between enabling technologies, translational pipelines, regulatory architecture, and the evolving ecosystem of suppliers, service providers, and end users.

Over recent years, the field has matured through iterative innovation in enzyme engineering, delivery platforms, and analytical methods. These technical improvements have expanded the scope of feasible projects, from single-gene edits in cell lines to complex multiplexed interventions in plants and animals. At the same time, the governance environment has become more active, with regulators and institutional review bodies clarifying expectations for clinical use, environmental release, and biosafety. This dual evolution of capability and oversight defines the strategic priorities for organizations investing in gene editing: demonstrating robust on-target performance, minimizing unintended outcomes, and ensuring compliant pathways to application.

In practical terms, stakeholders must balance scientific ambition with operational realities. Research institutions and commercial developers are increasingly focused on reproducible workflows, scalable manufacturing of biological materials, and robust quality-control frameworks. These operational improvements support both discovery and downstream development, enabling faster iteration cycles while maintaining data integrity. The remainder of this executive summary outlines the transformative shifts in the landscape, segmentation perspectives, regional dynamics, company-level behaviors, and pragmatic recommendations to inform strategic decision-making.

An incisive synthesis of the pivotal technological, operational, and regulatory shifts that are actively redefining development priorities and translational risk profiles

The last phase of technical and institutional evolution in gene editing has produced several transformative shifts that materially alter strategic considerations across research, development, and commercialization. First, refinement of editing modalities - including advances in precision editing that reduce collateral damage to genomic context - has shifted emphasis from proof of concept to optimization of safety and efficacy margins. Developers now prioritize orthogonal validation methods, high-resolution off-target assessment, and comprehensive functional characterization as prerequisites for translational decisions.

Second, delivery science has emerged as a central bottleneck and opportunity simultaneously. Improvements in viral vectors, lipid nanoparticles, and physical delivery techniques have increased the range of usable tissue types, but each approach imposes trade-offs between payload capacity, immunogenicity, and repeat dosing. Consequently, organizations are pursuing parallel strategies that combine editing chemistry innovation with bespoke delivery engineering to meet application-specific constraints.

Third, data-driven approaches are accelerating design cycles. Computational modeling, machine learning-enabled guide selection, and multiplexed screening platforms reduce empirical cycles and improve predictability. These approaches also enable more efficient candidate triage and risk assessment, supporting leaner development portfolios and clearer go/no-go criteria. Finally, regulatory and societal conversations around acceptable use, benefit-risk calculus, and equitable access are shaping commercial strategies; firms are embedding ethical and compliance considerations earlier in program design to avoid late-stage friction and to strengthen stakeholder trust.

A rigorous analysis of how tariff adjustments affect supply chain resilience, procurement strategies, and operational continuity across the gene editing development lifecycle

Policy changes that adjust import duties and trade barriers exert a complex set of influences across research and development ecosystems. When the United States implements tariff adjustments, the immediate impact is most visible in the procurement and distribution of specialized instrumentation, reagents, and consumables that underpin laboratory operations. Laboratories that rely on imported equipment or raw materials face elevated procurement costs and potential delays, which in turn incentivize longer lead times, increased inventory buffers, and expanded supplier qualification efforts.

Beyond procurement dynamics, tariffs contribute to shifts in global supply chain architecture. Organizations evaluate the resilience of existing vendor relationships and may accelerate efforts to qualify domestic or regional suppliers to reduce exposure to cross-border trade friction. This adaptation often entails additional validation work and qualification cycles that temporarily divert technical resources away from discovery activities. In parallel, multinational collaborations can encounter contractual renegotiations where duties alter total landed costs, creating friction for cross-border clinical manufacturing and collaborative research agreements.

Longer-term implications concern strategic sourcing and manufacturing footprint decisions. Service providers and contract manufacturers reassess the geographic distribution of their capabilities to mitigate tariff-related volatility, which can spur investment in regional capacity expansion or in vertical integration to internalize critical processes. Importantly, tariff-driven changes interact with regulatory requirements and clinical timelines; organizations that proactively manage supplier diversification and inventory risk are better positioned to maintain research continuity and to align operational plans with regulatory milestones.

A multidimensional segmentation framework that clarifies technology choices, application demands, and end user behaviors to guide strategic allocation of development resources

Segmentation offers a practical lens to understand technological pathways and application-driven priorities within gene editing. Based on CRISPR, market analysis commonly examines Cas12, Cas13, and Cas9, each of which presents distinct biochemical properties, target specificities, and application fit. Cas9 remains a versatile nuclease for DNA editing in many contexts, while Cas12 and Cas13 expand capabilities for single-strand targeting and RNA editing, enabling approaches that reduce permanent genomic alteration and that support transient modulation strategies.

Based on Technology, studies evaluate modalities including Antisense oligonucleotides, CRISPR-Cas9, Meganucleases, RNA-guided nucleases, TALENs (Transcription Activator-Like Effector Nucleases), and ZFNs (Zinc Finger Nucleases). Each technology exhibits a different balance of specificity, ease of design, and delivery constraints, which informs selection criteria for therapeutic programs versus agricultural or industrial applications. Antisense oligonucleotides and RNA-guided strategies commonly serve as lower-barrier interventions for transient gene modulation, whereas engineered nucleases like TALENs and ZFNs continue to play roles where locus-specific considerations demand alternative architectures.

Based on Application, the field spans Animal Genetic Engineering, Basic Research, Bioenergy, Cell Line Engineering, Diagnostics, Drug Development, Gene Editing, Plant Genetic Engineering, and Vaccine Development. Application context drives requirements for durability, target tissue, regulatory scrutiny, and acceptable risk, influencing both project timelines and technical choices. For example, diagnostics and cell line engineering prioritize rapid turnaround and reproducibility, while vaccine development and plant engineering emphasize scalability and environmental considerations.

Based on End User, the landscape comprises Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Organizations (CROs). Each end user segment exhibits unique procurement behaviors, risk tolerances, and collaboration models; academic institutions focus on exploratory research and publishable outputs, commercial developers aim for clinical translation and IP protection, and CROs provide operational capacity and regulatory-compliant processes that bridge discovery and commercial manufacturing. Understanding these segmentation axes in tandem enables more precise allocation of R&D resources and clearer prioritization of capability investments.

A comparative regional assessment that highlights regulatory nuances, infrastructure strengths, and strategic pathways for commercial and translational expansion across global hubs

Regional dynamics shape the innovation trajectory and operational choices in gene editing through differences in regulatory postures, talent pools, funding ecosystems, and industrial infrastructure. In the Americas, regulatory pathways are coupled with strong private investment and a dense clinical development ecosystem, which together accelerate translational programs and create robust markets for enabling technologies and services. Institutional review frameworks and centralized regulatory agencies provide predictable pathways for clinical translation, while a rich venture capital environment supports rapid scaling of platform companies and high-risk, high-reward projects.

In Europe, Middle East & Africa, stakeholders navigate a more heterogeneous regulatory environment where national approaches vary, and cross-border harmonization matters for multicountry trials and approvals. Europe's emphasis on ethical frameworks and public engagement shapes program design, particularly for environmental and agricultural applications. Public funding and collaborative consortia remain important drivers of precompetitive research, and capacity-building initiatives continue to expand access to advanced laboratory infrastructure across the region.

The Asia-Pacific region demonstrates rapid capacity expansion, large talent pipelines, and growing manufacturing capabilities. Regulatory approaches in several jurisdictions are evolving to support biotech innovation, and government-led initiatives frequently prioritize strategic sectors such as agriculture and healthcare. Combined with competitive manufacturing and supply chain ecosystems, this region is increasingly important for both clinical development and production of reagents and instruments. Each regional context requires tailored strategies for partnerships, regulatory engagement, and commercialization that reflect local regulatory expectations and market access considerations.

A strategic exploration of company behaviors and partnership models that reveal how platform developers, service providers, and clinical sponsors align to drive translational progress

Company behavior within the gene editing ecosystem varies by strategic orientation, capital structure, and operational capability. Tool and reagent providers focus on platform reliability, batch consistency, and regulatory-grade documentation to serve both discovery labs and regulated manufacturing. These suppliers invest in quality systems and technical support to reduce adoption friction and to enable customers to meet increasingly stringent validation requirements. Service providers and contract manufacturers emphasize capacity, process robustness, and compliance readiness to support clients moving from preclinical work to regulated clinical production.

Therapeutic developers prioritize target validation, clinical translation pathways, and risk mitigation strategies that align with regulatory expectations. Early-stage companies often concentrate on platform differentiation and IP position, while later-stage developers focus on clinical trial design, safety monitoring, and market access planning. Across the ecosystem, strategic partnerships and alliances serve as accelerators: collaborations between platform companies and clinical developers enable access to specialized chemistry or delivery solutions, while service-provider partnerships compress development timelines through integrated offerings.

Investment and M&A activity reflect the desire to consolidate capabilities and secure vertical integration in critical areas such as delivery and manufacturing. Companies that maintain clear go-to-market strategies, that invest in translational expertise, and that align product development with regulatory milestones are better positioned to capture opportunities and to de-risk program portfolios. Organizational agility, coupled with demonstrable quality systems, determines the pace at which firms can translate scientific advances into clinical and commercial outcomes.

A set of pragmatic, high-impact recommendations that operational leaders and program teams can implement immediately to strengthen translational readiness and risk mitigation

Leaders in research organizations and industry must act deliberately to translate scientific promise into durable outcomes. First, invest in integrated validation frameworks that combine molecular characterization, orthogonal functional assays, and standardized off-target analysis; this reduces downstream risk and strengthens regulatory narratives. Second, diversify supplier relationships early and qualify alternative sources for critical reagents and instruments to mitigate procurement shocks and to maintain research continuity. Third, embed delivery strategy alongside molecular design; co-development of delivery and editing chemistry often yields more predictable translational trajectories than sequential development.

Fourth, adopt data-driven design workflows that leverage computational prediction, high-throughput screening, and experimental feedback loops to accelerate candidate selection and to reduce iterative cycles. Fifth, engage regulators and ethics bodies proactively, sharing preclinical evidence and trial design rationale to reduce surprises and to align on safety requirements. Sixth, cultivate cross-sector partnerships with manufacturing and supply chain specialists to scale from proof of concept to regulated production while preserving quality systems and documentation.

Seventh, develop workforce capabilities by investing in training programs that bridge wet-lab expertise and translational project management; a multidisciplinary talent base accelerates program execution and improves governance. Finally, prioritize transparent stakeholder communication about benefit-risk considerations and risk-mitigation measures to build public trust and to support smoother pathways for clinical and agricultural applications. These actionable steps help organizations navigate technical complexity, regulatory expectations, and market uncertainties with greater confidence.

A transparent and evidence-driven methodology that integrates literature synthesis, expert interviews, and cross-segmentation analysis to produce actionable intelligence

The research approach underlying these insights combined systematic secondary research, targeted expert engagement, and iterative synthesis to ensure a robust evidence base. Secondary analysis drew on peer-reviewed literature, regulatory guidance documents, patent filings, and technical white papers to map technological trajectories and to identify recurring themes in validation practices and delivery strategies. This foundational review established a common knowledge baseline and highlighted areas requiring deeper qualitative inquiry.

Primary research involved structured interviews with subject-matter experts across academia, industry, and regulatory affairs. These conversations explored practical challenges in program execution, supply chain resilience, and compliance management, and they provided firsthand perspectives on the operational implications of recent technological advances. Triangulation of secondary and primary inputs ensured that findings reflect both documented evidence and real-world operational experience.

Analytic methods included qualitative coding to identify thematic patterns, cross-segmentation comparison to surface differences in technology and application fit, and scenario analysis to test supply chain and regulatory sensitivities. Quality assurance measures included expert review cycles and reconciliation of divergent viewpoints to minimize bias. The resulting synthesis emphasizes actionable intelligence that is directly relevant to program leaders, procurement teams, and strategic planners engaged in gene editing research and commercialization.

A concise synthesis that connects technical progress, operational readiness, and regulatory engagement into a coherent roadmap for advancing gene editing programs responsibly

Gene editing stands at a strategic inflection point where technological capability, regulatory evolution, and operational discipline converge to determine which programs progress from laboratory proof of concept to real-world application. The field's maturation requires not only continued technical innovation but also disciplined operational practices, proactive regulatory engagement, and strategic partnerships that bridge capability gaps. Organizations that align molecular design with delivery strategy, that diversify supply chains, and that prioritize rigorous validation will reduce translational risk and improve the probability of program success.

At the regional and organizational level, tailored approaches are essential. Regulatory nuances, infrastructure realities, and workforce strengths vary across geographies, and strategic plans must reflect these contextual differences. Companies and institutions should combine near-term operational resilience measures with longer-term investments in platform capabilities and translational talent. By doing so, they can both capitalize on immediate opportunities and build durable competitive advantages.

Ultimately, success in this domain depends on integrating scientific excellence with pragmatic execution. Clear governance, transparent stakeholder communication, and a disciplined approach to risk management will enable the most promising gene editing programs to move from concept to impact, delivering therapeutic, agricultural, and industrial benefits while maintaining public trust and regulatory compliance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Editing Market, by CRISPR

  • 8.1. Cas12
  • 8.2. Cas13
  • 8.3. Cas9

9. Gene Editing Market, by Technology

  • 9.1. Antisense oligonucleotides
  • 9.2. CRISPR-Cas9
  • 9.3. Meganucleases
  • 9.4. RNA-guided nucleases
  • 9.5. TALENs (Transcription Activator-Like Effector Nucleases)
  • 9.6. ZFNs (Zinc Finger Nucleases)

10. Gene Editing Market, by Application

  • 10.1. Animal Genetic Engineering
  • 10.2. Basic Research
  • 10.3. Bioenergy
  • 10.4. Cell Line Engineering
  • 10.5. Diagnostics
  • 10.6. Drug Development
  • 10.7. Gene Editing
  • 10.8. Plant Genetic Engineering
  • 10.9. Vaccine Development

11. Gene Editing Market, by End User

  • 11.1. Academic & Government Research Institutes
  • 11.2. Biotechnology & Pharmaceutical Companies
  • 11.3. Contract Research Organizations (CROs)

12. Gene Editing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Editing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Editing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Editing Market

16. China Gene Editing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Danaher Corporation
  • 17.8. GenScript Biotech Corporation
  • 17.9. Illumina, Inc.
  • 17.10. Lonza Group AG
  • 17.11. Merck KGaA
  • 17.12. New England Biolabs, Inc.
  • 17.13. PerkinElmer, Inc.
  • 17.14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE EDITING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE EDITING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE EDITING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE EDITING MARKET SIZE, BY CAS12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE EDITING MARKET SIZE, BY CAS12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE EDITING MARKET SIZE, BY CAS13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE EDITING MARKET SIZE, BY CAS13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE EDITING MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE EDITING MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE EDITING MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE EDITING MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE EDITING MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING MARKET SIZE, BY RNA-GUIDED NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING MARKET SIZE, BY RNA-GUIDED NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING MARKET SIZE, BY RNA-GUIDED NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING MARKET SIZE, BY TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING MARKET SIZE, BY TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING MARKET SIZE, BY TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING MARKET SIZE, BY ZFNS (ZINC FINGER NUCLEASES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE EDITING MARKET SIZE, BY ZFNS (ZINC FINGER NUCLEASES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE EDITING MARKET SIZE, BY ZFNS (ZINC FINGER NUCLEASES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING MARKET SIZE, BY ANIMAL GENETIC ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING MARKET SIZE, BY ANIMAL GENETIC ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING MARKET SIZE, BY ANIMAL GENETIC ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE EDITING MARKET SIZE, BY BIOENERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE EDITING MARKET SIZE, BY BIOENERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE EDITING MARKET SIZE, BY BIOENERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE EDITING MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE EDITING MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE EDITING MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE EDITING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE EDITING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE EDITING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE EDITING MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE EDITING MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE EDITING MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE EDITING MARKET SIZE, BY PLANT GENETIC ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE EDITING MARKET SIZE, BY PLANT GENETIC ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE EDITING MARKET SIZE, BY PLANT GENETIC ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE EDITING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE EDITING MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE EDITING MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE EDITING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE EDITING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE EDITING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE EDITING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE EDITING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE EDITING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS GENE EDITING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GCC GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 118. GCC GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. G7 GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 133. G7 GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NATO GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NATO GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 138. NATO GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA GENE EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA GENE EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA GENE EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)